Meet IAG’s Bio-Partnering Team at LSX World Congress, 2021
IAG’s team will be attending LSX World Congress, Feb 1, 2021 to Feb 12, 2021
IAG’s Bio-Partnering team is focusing on building a diversified portfolio of innovative life science companies at various stages of clinical development.
‘We are building partnerships, not just seeking business deals, with the goal to improve the quality of life for patients and maximize benefit in society’, said Dr. Olga Kubassova, CEO of IAG.
At IAG, we support novel drug or technology development efforts through conceptualisation, clinical trials to market entry by bringing strategic collaborators and smart investments.
We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immuno-oncology, oncology, inflammation, rheumatology, musculoskeletal, rare diseases, neuro-degenerative and immunology markets.
More on our recent partnerships can be found here: https://www.ia-grp.com/trial-solutions/bio-partnering/
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: email@example.com
Follow the Company: Linkedin